Kovack Advisors Inc. Has $253,000 Position in Stereotaxis, Inc. (NYSEAMERICAN:STXS)

Kovack Advisors Inc. trimmed its position in Stereotaxis, Inc. (NYSEAMERICAN:STXS) by 44.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,875 shares of the company’s stock after selling 99,901 shares during the period. Kovack Advisors Inc.’s holdings in Stereotaxis were worth $253,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of STXS. SG Americas Securities LLC bought a new stake in shares of Stereotaxis in the third quarter worth about $39,000. Forum Financial Management LP acquired a new position in shares of Stereotaxis in the 2nd quarter valued at approximately $48,000. Virtu Financial LLC raised its holdings in Stereotaxis by 56.0% during the 1st quarter. Virtu Financial LLC now owns 32,690 shares of the company’s stock worth $85,000 after buying an additional 11,739 shares during the period. Rhumbline Advisers lifted its stake in Stereotaxis by 645.6% in the second quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after buying an additional 41,780 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Stereotaxis by 247.5% in the second quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company’s stock valued at $345,000 after buying an additional 135,041 shares during the period. Institutional investors own 45.35% of the company’s stock.

Stereotaxis Trading Down 2.9 %

Shares of NYSEAMERICAN:STXS opened at $2.03 on Friday. The firm has a market cap of $171.86 million, a P/E ratio of -7.25 and a beta of 1.55. Stereotaxis, Inc. has a 12 month low of $1.47 and a 12 month high of $3.29.

Stereotaxis (NYSEAMERICAN:STXS) last released its quarterly earnings results on Monday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $9.20 million during the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 153.10%. Research analysts predict that Stereotaxis, Inc. will post -0.25 earnings per share for the current fiscal year.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.